JLJamie Jl Liew

Jamie Jl Liew

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamie Jl Liew has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk

    by Georgia Ramsay, Rachel Brooks, Christina Wade, Jamie Jie Mei Liew, Pavithran Alphonse, Jennifer G McIntosh, Laura E Forrest, Jon Emery, Sibel Saya

    Background: A polygenic risk score (PRS) enables personalisation of cancer risk and supporting risk stratification for melanoma, colorectal, breast, and prostate cancers. Including a PRS in a cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating an individual’s age, sex, family history, and genomic test results. GPs are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models. Aim: To elucidate GPs’ perspectives on the use of PRSs to tailor cancer screening in the Australian primary care context. Design & setting: A qualitative study undertaken in Victoria, Australia with GPs involved in a series of studies and clinical trials evaluating PRS. Method: Thirty GPs were interviewed; they were either PRS naive or had experience of using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia. Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research. Results: Common themes identified were: general practice is the appropriate setting for PRS-based approaches, personalised approaches to cancer risk can prompt discussions about positive lifestyle changes, and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included: time constraints on the delivery of preventative health care, education requirements to upskill GPs in genomics, possible psychosocial harms to patients identified as being at increased risk, life-insurance implications, and added pressure on an already struggling health system. Conclusion: These findings provide insight into the requirements for the implementation of PRSs in primary care, from the perspective of GPs.


  • Open Access

    The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

    by Sibel Saya, Patty Chondros, Anastasia Abela, Cathrine Mihalopolous, Mary Lou Chatterton, Jane Gunn, Timothy F. Chen, Thomas M. Polasek, Elise Dettmann, Rachel Brooks, et al.

    Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.


  • Open Access

    Immunohistochemistry in wholemounts and cryostat sections in rat stomach v1

    by Madeleine Di Natale, Jamie Jl Liew, Billie Hunne, Martin Stebbing, John Furness

    This protocol describes the methods used to evaluate neuronal target and population density in wholemount preparations and cryostat sections. In brief, stomachs from Sprague-Dawley rats were collected, fixed, cleared, and processed before being immunohistochemically stained with primary antibody and fluorescent secondary antibodies. Neuronal density and neuronal target analysis were completed using Zen Blue analysis software.

  • Open Access

    NADPH diaphorase histochemistry in rat gastric nitric oxide synthase neurons v1

    by Madeleine Di Natale, Billie Hunne, Jamie Jl Liew, Linda Fothergill, Martin Stebbing, John Furness

    NOS (nitric oxide synthase) is a NADPH oxidase, requiring NADPH as a proton donor for the conversion of arginine to citrulline and the production of nitric oxide (NO). Thus nitrergic neurons can be localised by nNOS immunoreactivity or histochemically, using the NADPH diaphorase reaction (Young et al. 1992) to enable investigation of their morphology.

  • Open Access

    Gene-environment-gut interactions in Huntington's disease mice are associated with environmental modulation of the gut microbiome

    by Carolina Gubert, Chloe Jane Love, Saritha Kodikara, Jamie Jie Mei Liew, Thibault Renoir, Kim-Anh Lê Cao, Anthony John Hannan


  • A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function

    by Ruslan V Pustovit, Xiaozhou Zhang, Jamie Jm Liew, Praveen Praveen, Mengjie Liu, Ada Koo, Lalita Oparija-Rogenmozere, Qinghao Ou, Martina Kocan, Shuai Nie, et al.